Navigating Bispecific Antibodies in Myeloma Care with Alfred Garfall, MD and Bea Razzo
Navigating Bispecific Antibodies in Myeloma Care with Alfred Garfall, MD and Bea Razzo
Event Description
This show will not be live streamed, it will be recorded on February 1st. You can submit your questions in advance here.
Bispecific antibodies are an increasingly popular choice for relapsed/refractory myeloma care. Learn more about this type of treatment with Dr. Alfred Garfall and Dr. Bea Razzo in this HealthTree Podcast. They will cover the FDA approved bispecific antibodies, those in development, how this changes the myeloma treatment landscape, sequencing, side effects and new strategies like a fixed duration that may reduce the treatment burden for patients.
Thanks to our episode sponsor,
Schedule & Agenda
Welcome, Announcements & Introduction
Welcome, Announcements & Introduction
An extensive discussion about bispecific antibodies in multiple myeloma.
An extensive discussion about bispecific antibodies in multiple myeloma.
Audience is able to submit their questions in advance so Drs. Garfall and Razzo can answer during the discussion.
Audience is able to submit their questions in advance so Drs. Garfall and Razzo can answer during the discussion.
Speakers & Moderators
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Dr. Garfall is Director of the Autologous Hematopoietic Stem Cell Transplantation program and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania.
Beatrice Razzo is currently a Hematology-Oncology Fellow at the University of Pennsylvania in Philadelphia. She performed her internship and residency at NYU Langone.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.